Relevant bibliographies by topics / Response to therapies / Books

Books on the topic 'Response to therapies'

To see the other types of publications on this topic, follow the link: Response to therapies.
Author: Grafiati
Published: 7 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 books for your research on the topic 'Response to therapies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Janusz, Rak, ed. Oncogene-directed therapies. Totowa, N.J: Humana Press, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Loes, Michael, and Michael W. Loes. The healing response. Topanga, Calif: Freedom Press, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Castro, Antonio de Miguel. Clopidogrel response in acute coronary syndrome: Clinical implications and emerging therapies. Hauppauge, N.Y: Nova Science Publishers, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

A, Foon Kenneth, and Muss Hyman B, eds. Biological and hormonal therapies of cancer. Boston: Kluwer Academic Publishers, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

L, Goldstein Allan, Garaci E, Institute for Advanced Studies in Immunology & Aging., and International Symposium on Combination Therapies (1st : 1991 : Washington, D.C.), eds. Combination therapies: Biological response modifiers in the treatment of cancer and infectious diseases. New York: Plenum Press, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

L, Goldstein Allan, Garaci E, Institute for Advanced Studies in Immunology & Aging., and International Symposium on Combination Therapies (2nd : 1992 : Acireale, Italy), eds. Combination therapies 2: Biological response modifiers in the treatment of cancer and infectious diseases. New York: Plenum Press, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Howard, Brody. The placebo response: How you can release the body's inner pharmacy for better health. New York: Cliff Street Books, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Valentine, Tom. Applied kinesiology: Muscle response in diagnosis, therapy and preventive medicine. Rochester, Vt: Thorsons Publishers, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Valentine, Tom. Applied kinesiology: Muscle response in diagnosis, therapy, and preventive medicine. Rochester, Vt: Healing Arts Press, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kradin, Richard L. The placebo response and the power of unconscious healing. New York: Routledge, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
11

Rogers, Annie G. Response to sexual abuse: Creativity and courage. Wellesley, MA: The Stone Center, Wellesley College, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
12

Christopher, Bird. The Galileo of the microscope: (the life and trials of Gaston Naessens). St. Lambert, Quebec, Canada: Les Presses de l'Universite' de la Personne, Inc., 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
13

Foa, Edna B. Exposure and ritual (response) prevention for obsessive compulsive disorder: Therapist guide. 2nd ed. Oxford: Oxford University Press, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
14

Klein, Catherine J. Recommendations for reviewing research on advanced first-responder resuscitation fluids and adjunct therapies. Bethesda, Md: Life Sciences Research Office, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
15

Christopher, Bird. The persecution and trial of Gaston Naessens: The true story of the efforts to suppress an alternative treatment for cancer, AIDS, and other immunologically based diseases. Tiburon, Calif: H.J. Kramer, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
16

Freeman, Veronica. The effects of touch in counselling/psychotherapy: Client response and therapists attitudes and behaviour. Guildford: University of Surrey, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
17

McHenry, Bill. What therapists say and why they say it: Effective therapeutic responses and techniques. Boston: Pearson/Allyn and Bacon, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
18

D, Rothblum Esther, and Cole Ellen, eds. A Woman's recovery from the trauma of war: Twelve responses from feminist therapists and activists. New York: Haworth Press, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
19

National Association of Paediatric Occupational Therapists. Excellence for all children: Meeting special educational needs : response by the National Association of Paediatric Occupational Therapists. [S.l.]: NAPOT, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
20

Rak, Janusz W. Oncogene-Directed Therapies. Humana Press, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
21

Foon, Kenneth A. Biological and Hormonal Therapies of Cancer. Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
22

Foon, Kenneth A., and Hyman B. Muss. Biological and Hormonal Therapies of Cancer. Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
23

Tyndall, Alan, and Jacob M. van Laar. Stem cell therapies. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0085.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Since the start of the international project in 1997, over 1500 patients have received a haematopoietic stem cell transplant (HSCT), mostly autologous, as treatment for a severe autoimmune disease, with overall 85% 5-year survival and 43% progression-free survival. Around 30% of patients in all disease subgroups had a complete response, often durable despite full immune reconstitution. In many cases, e.g. systemic sclerosis, morphological improvement such as reduction of skin collagen and normalization of microvasculature was documented, beyond any predicted known effects of intense immunosuppression alone. It is hoped that the results of the three running large prospective randomized controlled trials will allow modification of the protocols to reduce the high transplant-related mortality which relates to regimen intensity, age of patient, and comorbidity. Multipotent mesenchymal stromal cells (MSC) have been recently tested in various autoimmune diseases, exploiting their immune modulating properties and apparent low acute toxicity. MSC display immune privilege in that the patient requires no immunosuppression prior to allogeneic MSC infusion. Despite encouraging small phase I/II studies, no positive data from randomized prospective studies are as yet available in the peer-reviewed literature.
24

Tyndall, Alan, and Jacob M. van Laar. Stem cell therapies. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199642489.003.0085_update_003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Since the start of the international project in 1997, over 2000 patients have received a haematopoietic stem cell transplant (HSCT), mostly autologous, as treatment for a severe autoimmune disease, with overall 85% 5-year survival and 43% progression-free survival. Around 30% of patients in all disease subgroups had a complete response, often durable despite full immune reconstitution. In many cases, e.g. systemic sclerosis, morphological improvement such as reduction of skin collagen and normalization of microvasculature was documented, beyond any predicted known effects of intense immunosuppression alone. It is hoped that the results of the three running large prospective randomized controlled trials will allow modification of the protocols to reduce the high transplant-related mortality which relates to regimen intensity, age of patient, and comorbidity. Multipotent mesenchymal stromal cells (MSC) have been recently tested in various autoimmune diseases, exploiting their immune modulating properties and apparent low acute toxicity. MSC display immune privilege in that the patient requires no immunosuppression prior to allogeneic MSC infusion. Despite encouraging many small phase I/II studies, only 2 prospective controlled trials which achieved their primary endpoints have been published.
25

Benson, Lisa, and Andrew Christensen. Empirically Supported Couple Therapies. Edited by Erika Lawrence and Kieran T. Sullivan. Oxford University Press, 2014. http://dx.doi.org/10.1093/oxfordhb/9780199783267.013.003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
This article provides a comparative review of five empirically supported couple therapies: traditional behavioral couple therapy (behavioral marital therapy), cognitive behavioral couple therapy, insight-oriented couple therapy, emotionally focused couple therapy, and integrative behavioral couple therapy. The rationale for development of each treatment is given, with reference to differences from previous treatments. The specifics and typical sequence of interventions associated with each treatment are described. Empirical data on treatment outcomes, predictors of treatment response, and mechanisms of change are summarized for each treatment. Key points of convergence and divergence in approaches to treatment are noted.
26

Goldstein, Allan L., and E. Garaci. Combination Therapies: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases. Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
27

Goldstein, Allan L., and E. Garaci. Combination Therapies: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases. Springer London, Limited, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
28

Goldstein, Allan L., and E. Garaci. Combination Therapies: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases. Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
29

Goldstein, Allan L., and E. Garaci. Combination Therapies 2: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases. Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
30

Goldstein, Allan L., and E. Garaci. Combination Therapies 2: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases. Springer London, Limited, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
31

Brody, Daralyn, and Howard Brody. Placebo Response: How You Can Release the Body's Inner Pharmacy for Better Health. HarperCollins Canada, Limited, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
32

Valentine, Carole, Douglas P. Hetrick, and Tom Valentine. Applied Kinesiology: Muscle Response in Diagnosis, Therapy, and Preventive Medicine. Inner Traditions International, Limited, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
33

Brody, Howard, and Daralyn Brody. The Placebo Response: How You Can Release the Body's Inner Pharmacy for Better Health. Harper Perennial, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
34

Brody, Howard. The placebo response: How you can release the body's inner pharmacy for better health. Cliff Street Books, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
35

Valentine, Carole, Douglas P. Hetrick, and Tom Valentine. Applied Kinesiology: Muscle Response in Diagnosis, Therapy, and Preventive Medicine (Thorson's Inside Health Series). Healing Arts Press, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
36

Lincoln, Taylor, Shannon Haliko, and Jane Schell. Palliative Care Interventions: Role in Rapid Response Team Events (DRAFT). Edited by Raghavan Murugan and Joseph M. Darby. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190612474.003.0023.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Rapid response team (RRT) activation identifies hospitalized patients with acute illness who have a high symptom burden and are at increased risk for mortality and psychosocial distress. For many patients, the rapid response event presents itself as a final opportunity to avoid aggressive therapies that are unlikely to achieve patient-centered goals. Accumulating evidence supports an important role of the RRT in end-of-life care and the potential benefits of palliative care interventions by identifying at-risk patients who may benefit from readdressing goals of care (GOC) and facilitating a transition toward care that is most consistent with their preferences. This chapter outlines key palliative care skills that can be employed in the context of the RRT event including GOC discussion, patient/family support, and symptom management.
37

Moerdler, Scott, and Xingxing Zang. PD-1/PDL-1 Inhibitors as Immunotherapy for Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Programmed death 1 (PD-1), a member of the B7-CD28 immunoglobulin superfamily, and its ligands PD-L1/PD-L2 inhibit T-cell activation. They also play a key role in the tumor microenvironment, allowing for cancer immune escape. PD-1 is induced on a variety of immune cells, including tumor-infiltrating lymphocytes (TILs), while PD-L1 is found on many types of solid tumors including ovarian cancer and some TILs. The use of immunocheckpoint inhibitors like anti-PD-1 and anti-PD-L1 therapies has been shown to reactivate the immune system to attack tumor cells. Ovarian cancers have been shown to be responsive to anti-PD-1 and anti-PD-L1 therapies, though immunocheckpoint inhibitors are not enough. Current research is evaluating combination therapies to improve response rates.
38

Geri, Guillaume, and Jean-Paul Mira. Host–pathogen interactions in the critically ill. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0306.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Infection by a pathogenic micro-organism triggers a coordinated activation of both innate and adaptive immune responses. The innate immune response quickly triggers an antimicrobial response that will initiate development of a pathogen-specific, long-lasting adaptive immune response. Accurate recognition of microbial-associated molecular patterns by pattern-recognition receptors (PRRs) is the cornerstone of this immediate response. Most studied PRRs are Toll-like receptors (TLRs) and their kinase signalling cascades that activate nuclear transcription factors, and induce gene expression and cytokine production. Deficiencies or genetic variability in these different signalling pathways may lead to recurrent pyogenic infections and severe invasive diseases. After initial contact between the host and pathogen, numerous factors mediate the inflammatory response, as pro-inflammatory cytokines and chemokines. Apart from host genetic variability, pathogen diversity also influences the phenotypic features of various infectious diseases. Genomic analysis may assist in the development of targeted therapies or new therapeutic strategies based on both patient and microorganism genotype.
39

Osborne, David, and Chris Williams. Treatment. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780198801900.003.0011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
This chapter discusses talking therapies, or psychotherapies, for people with depression. For many years the predominant clinical model of depression has relied on medication as the gold standard for treatment. However, the cost of antidepressant medication prescribing is significant and rising. In response, recent government mental health targets also emphasize psychological interventions as an important treatment option. This chapter provides an overview of the characteristics of people who typically access talking therapies before turning to talking therapies that are available, including those that are recommended by national treatment guidelines such as NICE in England and Wales and SIGN in Scotland. In particular, it considers evidence-based talking therapies such as cognitive behavioural therapy, mindfulness-based cognitive therapy (MBCT), interpersonal therapy (IPT), and psychoanalysis and psychodynamic psychotherapy. The chapter also assesses the implications of talking therapies for clients of legal professionals.
40

Niaudet, Patrick, and Alain Meyrier. Minimal change disease. Edited by Neil Turner. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0056_update_001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Minimal change disease is characteristically responsive to high-dose corticosteroids. As this is the most common cause of nephrotic syndrome in children, and responses are usually prompt, response to 60 mg/m2/day of oral prednisolone (max. 80 mg) is often used as a diagnostic test. Adults respond more slowly and have a wider differential diagnosis, and often a high risk of side effects, so therapy is not recommended without confirmation by renal biopsy. Then first-line treatment is again prednisolone or prednisone, at 1 mg/kg/day (max. 60 mg). KDIGO and other treatment protocols recommend 6 weeks treatment at full dose then 6 weeks at half dose. Shorter protocols seem to increase the risk of relapse. Children frequently have a relapsing pattern of disease which may be managed by less extreme steroid exposure, but for which second-line therapies may be needed to avoid severe steroid side effects. This can arise in adults too. Some children and adults have steroid-dependent or steroid-resistant disease, leading to earlier initiation of treatment with second-line agents. These include levamisole, calcineurin inhibitors, mycophenolate mofetil, and anti-B cell antibodies. The evidence for these and recommendations for relapsing/resistant disease are given in this chapter.
41

Valpey, Robin, and Amy Crawford-Faucher. Behavioral Health Emergencies (DRAFT). Edited by Raghavan Murugan and Joseph M. Darby. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190612474.003.0016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Behavioral health emergencies typically involve agitation with autonomic instability. Many medical and psychiatric conditions can precipitate agitation that could necessitate rapid response interventions. Non-pharmacologic therapies can be useful to modulate agitation or delirium, but the mainstay of pharmacologic treatment is either antipsychotics or benzodiazepines, depending on the underlying problem. Psychosis and delirium generally respond better to antipsychotics, while mania, catatonia, toxidromes, withdrawal, and agitation from head injuries are more effectively treated with benzodiazepines. Prompt recognition of severe alcohol withdrawal can improve mortality; getting a history of other drug use, including “designer drugs” can help inform care. This chapter discusses the treatment of agitation, catatonia, medication-related disturbances, and intoxication and withdrawal during emergencies.
42

Wein, Simon, and Limor Amit. Adjustment disorders and anxiety. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199656097.003.0174.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Adjustment disorders and anxiety are two of the more common responses to stressors in palliative care. At one end of the spectrum, adjustment and anxiety are normal defences. However, when coping mechanisms fail these responses can become pathological. Judging when a response is pathological is based on two principles: the severity of symptoms and the extent of disruption of normal functioning or homeostatic adaptation. The intimate two-way relationship between physical and psychological symptoms in palliative care means that physical symptoms have to be well controlled and that psychological symptoms can be masked by physical complaints. Management principles include talking therapies, psychopharmacology, and complementary treatments. Examples of innovative psychological treatments are dignity therapy and meaning-centred therapy. Every palliative care intervention requires consideration of the family and it is also important to monitor anxiety and adjustment of the staff who are also prone to burn-out, compassion fatigue, and difficulties in adjusting to stressors.
43

Johnson, Emily L., and Mackenzie C. Cervenka. Dietary Therapy in Adults. Edited by Eric H. Kossoff. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190497996.003.0003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
First described over a century ago, dietary treatments for adults with epilepsy were rarely used until the last two decades. Studies show that ketogenic diets are feasible and effective in adults as well as children, and there is growing use in adults with medically refractory epilepsy. Children on ketogenic diets are also transitioning to adulthood and require ongoing neurology care. The classic ketogenic diet and the modified Atkins diet are most commonly used in adults. Results are encouraging, with response rates potentially rivaling those of new antiepileptic drugs. Dietary therapies offer adults with epilepsy an alternative that may reduce antiepileptic drug burden. While lipid elevations and gastrointestinal side effects are common, many patients find intentional weight loss and improved cognition as additional secondary benefits. The ketogenic diet is also a promising therapy for refractory status epilepticus in adults. This chapter examines the use of dietary therapies in adult epilepsy.
44

Vimalesvaran, Kavitha, and Michael Marber. Myocardial Remodelling after Myocardial Infarction. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199653461.003.0031.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
This chapter focuses on myocardial remodelling, a process that affects the heart’s shape, structure, and function, following myocardial injury (MI). Post-MI remodelling can be divided into three phases, with the first phase 0–72 hours beginning at the time of ischaemic injury, the second phase 72 hours to 6 weeks, and the third and last phase 6 weeks and beyond. During post-infarction remodelling, hypertrophy is an adaptive response that compensates for the increased load, reduces the effect of progressive dilatation, and balances contractile function. The chapter discusses the factors involved in ventricular remodelling and its association with heart failure progression. The effects of therapies designed to prevent or attenuate post-infarction left ventricular remodelling, with reference to the pathophysiological mechanisms involved, are then considered. Therapies specifically discussed include angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), β‎-adrenoreceptor blockers, and aldosterone receptor antagonists.
45

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, and Gareth Morris-Stiff. Targeted and biological therapies. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Hormone therapy describes the role of hormones in the growth of a variety of cancers, and the therapeutic effects of manipulation of hormone levels in these diseases. Sex hormones stimulate the growth of breast and prostate cancers, many of which respond to surgical removal of the hormone-secreting gonad. Pharmacological measures to deliver hormone therapy in these diseases include luteinising hormone releasing hormone (LHRH) agonists and antagonists, inhibitors of sex hormone synthesis, and inhibitors of hormone-receptor binding. These treatments have established benefits in both in the control of advanced disease and the adjuvant therapy of early-stage disease. The pros and cons of combination hormone therapy are discussed. Resistance to hormone therapy may be primary or acquired, and the likely mechanisms are described.
46

Venet, Fabienne, and Alain Lepape. Immunoparesis in the critically ill. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0313.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
In parallel with an exaggerated pro-inflammatory response, critically-ill patients develop an immunosuppressive phase, termed immunoparesis/immunoparalysis or immune reprogramming. Innate and adaptive immune responses are affected. In particular, impaired neutrophil recruitment to injury sites and abnormal accumulation in remote sites; monocyte deactivation with preferential anti-inflammatory cytokine production and altered antigen presentation capacity; and a dramatic lymphopenia associated with major induction of apoptosis, functional, and phenotypic alterations have been described. The intensity and duration of this injury-induced immune dysfunction have been associated with an increased risk of death and secondary nosocomial infections. Innovative therapeutic strategies aiming at restoring immunological functions are currently being tested. GM-CSF appears to be an interesting candidate while IFN-γ‎ and IL-7 represent novel future therapeutic approaches. There is thus an urgent need for further clinical trials of such immunoadjuvant therapies that should include large cohorts of critically-ill patients stratified by relevant markers of immune dysfunction.
47

Shils, Jay L., Sepehr Sani, Ryan Kochanski, Mena Kerolus, and Jeffrey E. Arle. Recording Techniques Related to Deep Brain Stimulation for Movement Disorders and Responsive Stimulation for Epilepsy. Edited by Donald L. Schomer and Fernando H. Lopes da Silva. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190228484.003.0038.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Neuromodulation therapies are now common treatments for a variety of medically refractory disorders, including movement disorders and epilepsy. While surgical techniques for each disorder vary, electricity is used by both for relieving symptoms. During stereotactic placement of the stimulating electrode, either deep brain stimulation electrodes or cortical strip electrodes, intraoperative neurophysiology is used to localize the target structure. This physiology includes single-unit recordings, neurostimulation evoked response evaluation, and intracranial electroencephalography (EEG) to ensure the electrode leads are in the optimal location. Because the functional target for the responsive neurostimulator is more easily visualized on preoperative magnetic resonance imaging, intraoperative physiology is used more as a confirmatory tool, in contrast to the more functional localization-based use during electrode placement for movement disorders. This chapter discusses surgical placement of the electrodes for each procedure and the physiological guidance methodology used to place the leads in the optimal location.
48

Mease, Philip. Biologic treatments for psoriatic arthritis apart from TNF inhibition. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198737582.003.0030.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Psoriatic arthritis (PsA) is an immunologically mediated inflammatory disease characterized by arthritis, enthesitis, dactylitis, spondylitis, and psoriasis. Prior to the introduction of targeted biologic medications, such as TNF inhibitors, the ability to control disease activity was limited, with only modest effects noted with traditional oral medications such as methotrexate and sulfasalazine. The introduction of TNF inhibitors substantially changed the outlook of PsA patients, yielding significant response in all relevant clinical domains and demonstrating the ability to inhibit progressive structural damage of joints. However, not all patients responded to these agents and many patients displayed initial response which waned over time, partly due to immunogenicity (development of antibodies which blocked full therapeutic effect of the biologic protein), or because of tolerability and side effect issues. Thus, it has been important to develop new medicines which target other key cytokines and immunologic pathways. Several medicines with a different mechanism of action have been approved or are in development for the treatment of PsA. Ustekinumab inhibits both IL12 and IL23 and thus is felt to work in both the TH1 and TH7 pathways of inflammation. The oral medicine apremilast inhibits phosphodiesterase 4, thus modulating the cyclic AMP pathway in immunologic cells, yielding an anti-inflammatory effect. Both of these medicines have been approved for the treatment of PsA as well as psoriasis. An emerging group of therapies, the IL17 inhibitors, has demonstrated significant effectiveness in psoriasis and PsA and one of these, Secukinumab, has been approved for psoriasis, PsA, and AS. Other medicines in development include the co-stimulatory blockade agent, abatacept, oral Janus Kinase (JAK) inhibitors, and an emerging group of therapies which inhibit IL23. As modulators of immune cell function, these agents have the potential to increase risk for infection, as well as other side effects. These must be discussed with the patient and considered when determining overall risk benefit analysis regarding their use. The emergence of medicines with a different mechanism of action than TNF inhibition has broadened and strengthened our ability to effectively treat PsA.
49

Kanner, Andres M. Depression in Neurological Disorders. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190603342.003.0007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Depression is a common psychiatric comorbidity in the major neurologic disorders (e.g, stroke, epilepsy, migraine, Alzheimer’s dementia, multiple sclerosis, and Parkinson’s disease), with average prevalence rates of 25% to 40%. The relation between depression and several of these neurologic disorders is bidirectional, that is not only are patients with these neurologic conditions at greater risk of developing depression, but patients with depression are at greater risk of developing these neurologic disorders. Furthermore, the presence of comorbid depression has been associated with a worse course of the neurologic disorder and a higher risk of failure to respond to the neurologic therapies. This chapter reviews the epidemiologic and clinical characteristics of depression in the major neurologic disorder and describes the impact it has on the course of the neurologic condition and response to treatment. Finally, it identifies those neurologic disorders in with a bidirectional relation has been identified and suggests potential pathogenic mechanisms that may be operant in their complex relation.
50

Exposure And Response Ritual Prevention For Obsessivecompulsive Disorder Therapist Guide. Oxford University Press, USA, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Response to therapies' for other source types:
Journal articles Dissertations / Theses

To the bibliography